Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 5.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krishna Institute of Medical Sciences reported audited consolidated results for Q4 and full year FY2026 ended March 31, 2026. Total consolidated revenue grew ~24% to Rs 16,120 million from ~Rs 12,978 million in the prior year. Profit after tax (after non-controlling interests) came in at Rs 2,000 million for the year. Auditors S.R. Batliboi & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated results. An exceptional item of Rs 74 million was recorded due to a one-time increase in employee benefit provisions from the implementation of the new Labour Codes effective November 21, 2025. The company also appointed new senior management including a CFO and re-designated Mr. Adwik Bollineni (son of the CMD and brother of the CEO) as an Executive Director.
The company delivered strong revenue growth above 20% with clean audit findings, which is broadly positive for investors. However, the large exceptional item and related-party re-designation may attract scrutiny. The significant increase in borrowings (long-term debt rose to Rs 26.7bn from Rs 16.5bn) warrants monitoring.